Drugs / ISIS 333611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01041222 | Jan 2010 → Dec 2011 | familial amyotrophic lateral sclerosis | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2007-12-13 | Ionis Pharmaceuticals | Regulatory Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to ISIS 333611 for the treatment of an inherited form of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-12-13 | Ionis Pharmaceuticals | Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS ionis.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 333611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01041222 ↗ |
| Action | Inhibit | “the antisense oligonucleotide ISIS 333611 delivered to CSF decreased SOD1 mRNA and protein concentrations” PMID 23541756 ↗ Mar 2013 |
| Modality | Antisense oligonucleotide | “An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis” PMID 23541756 ↗ Mar 2013 |
| Route | Intrathecal | “we delivered ISIS 333611 by intrathecal infusion” PMID 23541756 ↗ Mar 2013 |
| Target | SOD1 | “An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis” PMID 23541756 ↗ Mar 2013 |